Tocilizumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 7670 publications

Immune Imbalance Drives Keloid Pathogenesis: Emerging Targets for Precision Immunotherapy.

Immune Imbalance Drives Keloid Pathogenesis: Emerging Targets for Precision Immunotherapy.

Journal: Advances in wound care

Published: January 23, 2026

Recommendations for screening for latent tuberculosis infection in people with rheumatic diseases: Consensus statement from the Singapore Chapter of Rheumatologists.

Recommendations for screening for latent tuberculosis infection in people with rheumatic diseases: Consensus statement from the Singapore Chapter of Rheumatologists.

Journal: Annals of the Academy of Medicine, Singapore

Published: January 21, 2026

Thinking Outside the Box: Managing Refractory Antibody-Mediated Rejection Based on Injury-Related Phenotype to Preserve Renal Function in Patients Where Multiple Rounds of Standard Care Treatment Have Failed.

Thinking Outside the Box: Managing Refractory Antibody-Mediated Rejection Based on Injury-Related Phenotype to Preserve Renal Function in Patients Where Multiple Rounds of Standard Care Treatment Have Failed.

Journal: Journal of intensive care medicine

Published: January 21, 2026

Towards effective targeted therapies in morphea.

Towards effective targeted therapies in morphea.

Journal: Italian journal of dermatology and venereology

Published: January 12, 2026

A Case of VEXAS Syndrome.

A Case of VEXAS Syndrome.

Journal: WMJ : official publication of the State Medical Society of Wisconsin

Published: January 07, 2026

Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis.

Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis.

Journal: bioRxiv : the preprint server for biology

Published: January 07, 2026

VEXAS Syndrome with Vibrio vulnificus Sepsis During Treatment with Tocilizumab: A Case Report.

VEXAS Syndrome with Vibrio vulnificus Sepsis During Treatment with Tocilizumab: A Case Report.

Journal: Internal medicine (Tokyo, Japan)

Published: January 04, 2026

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care.

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care.

Journal: Journal of medical economics

Published: January 03, 2026

Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature.

Tocilizumab in immune checkpoint inhibitor-induced myositis, myocarditis, and myasthenic syndrome: a rare case report and review of the literature.

Journal: ARP rheumatology

Published: January 02, 2026

Comparative Outcomes of Teprotumumab and Tocilizumab in Thyroid Eye Disease: The First Retrospective Study from the United Arab Emirates and Gulf Region of the Middle East.

Comparative Outcomes of Teprotumumab and Tocilizumab in Thyroid Eye Disease: The First Retrospective Study from the United Arab Emirates and Gulf Region of the Middle East.

Journal: Seminars in ophthalmology

Published: December 24, 2025

Systemic Sclerosis-Associated Interstitial Lung Disease: Improved Understanding and Advances in Management.

Systemic Sclerosis-Associated Interstitial Lung Disease: Improved Understanding and Advances in Management.

Journal: British journal of hospital medicine (London, England : 2005)

Published: December 24, 2025

Targeting inflammation in endometriosis: emerging therapeutic options.

Targeting inflammation in endometriosis: emerging therapeutic options.

Journal: Expert opinion on investigational drugs

Published: December 24, 2025

Showing 1-12 of 7,670

Last Updated: 02/24/2026